FDA Awards Orphan Drug Designation to ABD-147 for Neuroendocrine Carcinoma
FDA grants orphan drug designation to ABD-147, a next-gen radiopharmaceutical targeting DLL3-expressing neuroendocrine carcinomas. Developed using the ROVEr™ platform, ABD-147 aims to deliver Actinium-225 to tumors while sparing healthy cells. Plans include a phase 1 trial in SCLC and large cell neuroendocrine carcinoma patients.
Reference News
FDA grants orphan drug designation to ABD-147 for neuroendocrine carcinoma treatment. ABD-147, a precision radiopharmaceutical, targets DLL3-expressing tumors. A phase 1 study will evaluate its efficacy in SCLC and LCNEC patients previously treated with platinum-based therapy.
FDA grants orphan drug designation to ABD-147, a next-gen radiopharmaceutical targeting DLL3-expressing neuroendocrine carcinomas. Developed using the ROVEr™ platform, ABD-147 aims to deliver Actinium-225 to tumors while sparing healthy cells. Plans include a phase 1 trial in SCLC and large cell neuroendocrine carcinoma patients.